[go: up one dir, main page]

TR200000065T2 - Epotilon türevleri. - Google Patents

Epotilon türevleri.

Info

Publication number
TR200000065T2
TR200000065T2 TR2000/00065T TR200000065T TR200000065T2 TR 200000065 T2 TR200000065 T2 TR 200000065T2 TR 2000/00065 T TR2000/00065 T TR 2000/00065T TR 200000065 T TR200000065 T TR 200000065T TR 200000065 T2 TR200000065 T2 TR 200000065T2
Authority
TR
Turkey
Prior art keywords
formula
epothilone derivatives
iii
group
substituted
Prior art date
Application number
TR2000/00065T
Other languages
English (en)
Inventor
D. Vite Gregory
M. Borzilleri Robert
Kim Soong-Hoon
A. Johnson James
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26729990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000065(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of TR200000065T2 publication Critical patent/TR200000065T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Mevcut bulus, formül (I)'e ait bilesiklerle ilgilidir; Q, (II)' nin olusturdugu gruptan seçilmistir; G; alkil, ikame edilmis alkil, ikame edilmis veya ikame edilmemis aril, heterosiklo, (III)' ün olusturdugu gruptan seçilmistir.(Formül (I),Formül (II),Formül (III)).
TR2000/00065T 1997-07-08 1998-06-16 Epotilon türevleri. TR200000065T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5195197P 1997-07-08 1997-07-08
US6752497P 1997-12-04 1997-12-04

Publications (1)

Publication Number Publication Date
TR200000065T2 true TR200000065T2 (tr) 2000-11-21

Family

ID=26729990

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00065T TR200000065T2 (tr) 1997-07-08 1998-06-16 Epotilon türevleri.

Country Status (32)

Country Link
US (10) US6605599B1 (tr)
EP (4) EP1531153A1 (tr)
JP (2) JP4090514B2 (tr)
KR (1) KR100569041B1 (tr)
CN (1) CN100384834C (tr)
AR (1) AR013358A1 (tr)
AT (2) ATE309236T1 (tr)
AU (1) AU731497B2 (tr)
BG (1) BG64952B1 (tr)
BR (1) BRPI9810555A8 (tr)
CA (1) CA2296012C (tr)
CO (1) CO4940501A1 (tr)
CZ (1) CZ297904B6 (tr)
DE (2) DE69840693D1 (tr)
DK (1) DK1019389T3 (tr)
EE (1) EE04566B1 (tr)
EG (1) EG24464A (tr)
ES (2) ES2322807T3 (tr)
GE (1) GEP20032897B (tr)
HU (1) HU227444B1 (tr)
ID (1) ID23771A (tr)
IL (1) IL133613A (tr)
LV (1) LV12569B (tr)
MY (1) MY124151A (tr)
NO (1) NO322494B1 (tr)
NZ (1) NZ501198A (tr)
PE (1) PE104599A1 (tr)
PL (1) PL197404B1 (tr)
RO (1) RO120340B1 (tr)
TR (1) TR200000065T2 (tr)
TW (1) TW562802B (tr)
WO (1) WO1999002514A2 (tr)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DK0941227T5 (da) * 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
BR9916833A (pt) * 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
AU4101800A (en) * 1999-02-11 2000-08-29 Schering Aktiengesellschaft Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU772750C (en) 1999-04-30 2005-02-24 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
IL155306A0 (en) 2000-10-13 2003-11-23 Univ Mississippi Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
MXPA03006485A (es) 2001-01-25 2003-09-22 Bristol Myers Squibb Co Formulacion parenteral que contiene analogos de epotilona.
JP4633331B2 (ja) * 2001-01-25 2011-02-16 ブリストル−マイヤーズ スクイブ カンパニー 癌治療のためのエポチロン類似体の投与方法
BRPI0206509B8 (pt) 2001-01-25 2021-05-25 R Pharm Us Operating Llc processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1385529A4 (en) 2001-02-20 2007-05-09 Bristol Myers Squibb Co TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES
MXPA03007423A (es) 2001-02-20 2003-11-18 Bristol Myers Squibb Co Derivados de epotilona para tratamiento de tumores refractarios.
NZ539204A (en) 2001-02-27 2005-12-23 Biotechnolog Forschung Gmbh Degradation of epothilones and ethynyl substituted epothilones
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
EP1392664A4 (en) 2001-06-01 2005-01-26 Bristol Myers Squibb Co EPOTHILONE DERIVATIVES
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
IL162595A0 (en) 2002-01-14 2005-11-20 Novartis Ag Combinations comprising epothilones and antimetabolites
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
DK1483251T3 (da) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
DE10232094A1 (de) * 2002-07-15 2004-02-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 5-Thiaepothilone und 15-disubstituierte Epothilone
PT1506203E (pt) 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN1705662B (zh) 2002-09-23 2011-07-06 布里斯托尔-迈尔斯斯奎布公司 埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构
HK1080369A1 (zh) * 2002-10-11 2006-04-28 Dana-Farber Cancer Institute, Inc. 用於治疗多发性骨髓瘤的埃博霉素衍生物
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
DK1567524T3 (da) * 2002-11-28 2009-11-16 Wolfgang Richter Thia-epothilonderivater til behandling af cancer
JP2006515291A (ja) * 2002-12-09 2006-05-25 ノバルティス アクチエンゲゼルシャフト ステントに入れて狭窄症を処置するための微小管安定化剤
GB0230024D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
CN100359014C (zh) * 2003-01-28 2008-01-02 北京华昊中天生物技术有限公司 一类新型埃坡霉素化合物及其制备方法和用途
WO2004071440A2 (en) 2003-02-06 2004-08-26 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2008200555C1 (en) * 2003-03-14 2011-12-15 Novartis Ag Treatment of proliferative diseases with epothilone derivatives and radiation
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
DE10344882A1 (de) * 2003-09-26 2005-04-21 Morphochem Ag Komb Chemie Neue Makrocyclen zur Behandlung von Krebserkrankungen
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
WO2005054429A2 (en) * 2003-11-19 2005-06-16 The University Of Mississippi Synthesis of the c1-c6 keto-acid synthon of the epothilones
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2006017761A2 (en) * 2004-08-05 2006-02-16 Emory University Epothilone analogues as therapeutic agents
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
MX2007005763A (es) 2004-11-18 2007-07-20 Squibb Bristol Myers Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma.
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US20110104664A1 (en) 2006-03-31 2011-05-05 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
WO2008070672A2 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and cpg rich dna
CN101668536A (zh) 2007-02-08 2010-03-10 伊利诺斯大学理事会 用铜氧还蛋白预防癌症的组合物和方法
EP2152717A1 (en) 2007-05-25 2010-02-17 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
US20090076099A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched ixabepilone
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
JP2011509299A (ja) 2008-01-08 2011-03-24 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
AR071598A1 (es) * 2008-04-24 2010-06-30 Bristol Myers Squibb Co Uso de epotilona dpara el tratamiento de enfermedades asociadas a tau incluso enfermedad de alzheimer
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
JP4500951B1 (ja) * 2009-08-07 2010-07-14 学校法人神戸学院 Ｄｎａ合成酵素阻害剤
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
HUE035059T2 (hu) 2009-11-05 2018-05-02 Rhizen Pharmaceuticals S A Új benzopirán-kinát modulátorok
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
KR101871436B1 (ko) 2010-05-17 2018-06-27 인코젠 쎄라퓨틱스 프라이빗 리미티드 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
JP2013527239A (ja) 2010-06-01 2013-06-27 プラス・ケミカルス・エスアー イクサベピロンの固体形
CN101906099A (zh) * 2010-07-16 2010-12-08 泰州市今朝伟业精细化工有限公司 一种埃博霉素d-内酰胺衍生物化学合成方法
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
US20140193752A1 (en) * 2011-04-01 2014-07-10 The Research Foundation Of State University Of New York Stabilized acid amplifiers
US20140087309A1 (en) * 2011-04-01 2014-03-27 The Research Foundation Of State University Of New York Olefin-triggered acid amplifiers
ES2710874T3 (es) 2011-05-04 2019-04-29 Rhizen Pharmaceuticals S A Compuestos novedosos como moduladores de proteína cinasas
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
KR102087854B1 (ko) 2011-06-10 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-중합체-약물 접합체
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
WO2013008091A1 (en) * 2011-07-13 2013-01-17 Xellia Pharmaceuticals Aps Manufacturing of epothilone derivatives and the use thereof
ES2458220T3 (es) 2011-09-12 2014-04-30 Agfa-Gevaert Métodos para el marcado por láser color de precursores de documento de seguridad
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
CN104321322A (zh) 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
US9725477B2 (en) 2012-11-17 2017-08-08 Beijing Fswelcome Technology Development Co., Ltd Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
TWI520956B (zh) * 2013-03-08 2016-02-11 台灣神隆股份有限公司 伊莎匹隆及其中間體之製備方法
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
MX2015017120A (es) 2013-06-11 2016-10-05 Bayer Pharma AG Combinaciones para el tratamiento de cancer que comprende un inhibidor de la quinasa mps-1 y un inhibidor de la mitosis.
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
WO2014202775A1 (en) 2013-06-21 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
US10316080B2 (en) 2013-10-11 2019-06-11 Asana Biosciences, Llc Protein-polymer-drug conjugates
US10341459B2 (en) 2015-09-18 2019-07-02 International Business Machines Corporation Personalized content and services based on profile information
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP3474901B1 (en) 2016-06-27 2025-08-06 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
JP7320458B2 (ja) 2017-06-22 2023-08-03 メルサナ セラピューティクス インコーポレイテッド 薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
CA3099421C (en) 2018-05-04 2025-05-06 Tagworks Pharmaceuticals B.V. COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY
US20210299286A1 (en) 2018-05-04 2021-09-30 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
CN113365664A (zh) 2018-10-29 2021-09-07 梅尔莎纳医疗公司 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
DK3983363T3 (da) 2019-06-17 2024-06-24 Tagworks Pharmaceuticals B V Forbindelser til hurtig og effektiv klikfrigivelse
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
EP4087545A1 (en) 2020-01-10 2022-11-16 R-Pharm US Operating LLC Compositions of ixabepilone
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2023031445A2 (en) 2021-09-06 2023-03-09 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
CA3238627A1 (en) 2021-11-25 2023-06-01 Christine Kohler Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
DK4186529T3 (da) 2021-11-25 2025-08-25 Veraxa Biotech Gmbh Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
EP4444356A1 (en) 2021-12-08 2024-10-16 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
IL314951B2 (en) 2022-02-15 2025-07-01 Tagworks Pharmaceuticals B V Masked il12 protein
EP4554624A1 (en) 2022-07-15 2025-05-21 Pheon Therapeutics Ltd Antibody-drug conjugates
EP4602023A1 (en) 2022-10-12 2025-08-20 Tagworks Pharmaceuticals B.V. Strained bicyclononenes
WO2024153789A1 (en) 2023-01-20 2024-07-25 Basf Se Stabilized biopolymer composition, their manufacture and use
KR20250169530A (ko) 2023-03-10 2025-12-03 태그웍스 파마슈티컬스 비.브이. 개선된 t-링커를 갖는 트랜스-사이클로옥텐
AU2024300552A1 (en) 2023-07-27 2026-01-29 Veraxa Biotech Gmbh Hydrophilic trans-cyclooctene (hytco) compounds, constructs and conjugates containing the same
WO2025056807A1 (en) 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025174248A1 (en) 2024-02-16 2025-08-21 Tagworks Pharmaceuticals B.V. Trans-cyclooctenes with "or gate" release

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272525A (en) * 1978-10-23 1981-06-09 Schering Corporation Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them
AU561147B2 (en) 1982-09-13 1987-04-30 Eli Lilly And Company 20-amino macrolide antibiotics
US4820695A (en) * 1982-09-13 1989-04-11 Eli Lilly And Company C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
JPH03101679A (ja) 1989-09-14 1991-04-26 Sankyo Co Ltd リゾキシン誘導体
US5798345A (en) * 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
US5786348A (en) * 1991-01-08 1998-07-28 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2
TW221028B (tr) 1991-05-02 1994-02-11 Lilly Co Eli
US5217960A (en) 1991-05-03 1993-06-08 Abbott Laboratories Erythromycin derivatives
JP3101679B2 (ja) 1991-07-02 2000-10-23 株式会社ニチレイ 動物細胞の凍結保存用血清不含培地及び保存方法
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
TW226373B (tr) * 1992-07-15 1994-07-11 Pfizer
EP0586738A1 (en) 1992-09-11 1994-03-16 Boehringer Ingelheim Vetmedica Gmbh Enhanced chemotherapeutic compositions against microbial infections in fish containing a benzylamine derivative and an antimicrobial substance
CN1093371A (zh) 1992-12-21 1994-10-12 伊莱利利公司 水生生物革兰氏阳性疾病的治疗
US5677287A (en) 1993-03-18 1997-10-14 Pfizer Inc. Antibacterial 16-membered ring macrolides containing olefins at C-20
DE4316836A1 (de) 1993-05-19 1994-11-24 Knoell Hans Forschung Ev Tetrahydrofuranyl-propionsäure, ein Verfahren zu ihrer Herstellung und Verwendung derselben
DE69402714T2 (de) * 1993-07-15 1997-07-31 Pfizer Amid-derivate von 16-gliedrige heterocyclen als antibiotische macrolide
SG49853A1 (en) * 1993-08-16 2001-07-24 Novartis Ag Novel macrolides and the use thereof
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
WO1996009312A1 (en) 1994-09-22 1996-03-28 Pfizer Inc. Antibiotic macrolides
WO1996011398A1 (en) 1994-10-07 1996-04-18 Merck & Co., Inc. Process for assessing tubulin protein polymerization
IL117200A0 (en) 1995-02-21 1996-06-18 Schering Ag Diethylenetriamine-pentaacetic acid monoamide derivatives pharmaceutical compostions containing the same and processes for the preparation thereof
US6124453A (en) * 1995-07-04 2000-09-26 Novartis Ag Macrolides
US5515936A (en) * 1995-07-10 1996-05-14 Vehicules Ts Bellechasse Ltee Track tensioning system for endless track propelled vehicle
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
WO1997019088A1 (en) 1995-11-21 1997-05-29 Hoechst Celanese Corporation Novel nonlinear optical molecules and polymers incorporating them
EP0778283A3 (en) 1995-12-05 1998-01-28 Pfizer Inc. Antibiotic macrolides
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
GB9623944D0 (en) 1996-11-15 1997-01-08 Zeneca Ltd Bicyclic amine derivatives
DK0941227T5 (da) 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
AT404477B (de) 1997-01-15 1998-11-25 Thal Hermann Dipl Ing Gebündeltes spannglied und verfahren zur herstellung desselben
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
CN1128803C (zh) 1997-02-25 2003-11-26 生物技术研究有限公司(Gbf) 环氧噻嗪酮b－n－氧化物及其制备方法
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
EP0975622B1 (de) 1997-04-18 2002-10-09 Studiengesellschaft Kohle mbH Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PT1001951E (pt) 1997-07-16 2003-02-28 Schering Ag Derivados de tiazolo, processo para a sua preparacao e utilizacao
US7407975B2 (en) 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
AU753519B2 (en) 1998-02-05 2002-10-17 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6136630A (en) * 1998-06-04 2000-10-24 The Regents Of The University Of Michigan Method of making a micromechanical device from a single crystal semiconductor substrate and monolithic sensor formed thereby
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
DE50014587D1 (de) 1999-02-18 2007-10-04 Bayer Schering Pharma Ag 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AU772750C (en) 1999-04-30 2005-02-24 Schering Aktiengesellschaft 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
MXPA03006485A (es) * 2001-01-25 2003-09-22 Bristol Myers Squibb Co Formulacion parenteral que contiene analogos de epotilona.
BRPI0206509B8 (pt) 2001-01-25 2021-05-25 R Pharm Us Operating Llc processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
EP1385529A4 (en) 2001-02-20 2007-05-09 Bristol Myers Squibb Co TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
US7026362B2 (en) 2001-10-09 2006-04-11 Simax Technologies, Inc. Sol-gel process utilizing reduced mixing temperatures

Also Published As

Publication number Publication date
KR20010021562A (ko) 2001-03-15
US20150080440A1 (en) 2015-03-19
MY124151A (en) 2006-06-30
US20070255055A1 (en) 2007-11-01
ATE426598T1 (de) 2009-04-15
ID23771A (id) 2000-05-11
HK1026905A1 (en) 2000-12-29
RO120340B1 (ro) 2005-12-30
NO20000076D0 (no) 2000-01-07
ES2251088T3 (es) 2006-04-16
NO322494B1 (no) 2006-10-16
JP2007291121A (ja) 2007-11-08
EG24464A (en) 2009-07-16
EP1493738B1 (en) 2009-03-25
EP1526133A1 (en) 2005-04-27
WO1999002514A2 (en) 1999-01-21
HU227444B1 (en) 2011-06-28
CA2296012A1 (en) 1999-01-21
AU731497B2 (en) 2001-03-29
DK1019389T3 (da) 2006-01-16
HUP0103111A2 (hu) 2002-04-29
PE104599A1 (es) 2000-01-19
PL338003A1 (en) 2000-09-25
JP2002512634A (ja) 2002-04-23
JP4885067B2 (ja) 2012-02-29
US6605599B1 (en) 2003-08-12
NO20000076L (no) 2000-01-07
CO4940501A1 (es) 2000-07-24
KR100569041B1 (ko) 2006-04-10
US7241755B2 (en) 2007-07-10
BG64952B1 (bg) 2006-10-31
BR9810555A (pt) 2000-08-15
AU7972098A (en) 1999-02-08
LV12569A (en) 2000-11-20
CA2296012C (en) 2008-10-21
EP1019389A2 (en) 2000-07-19
CZ297904B6 (cs) 2007-04-25
PL197404B1 (pl) 2008-03-31
EP1019389B1 (en) 2005-11-09
USRE41893E1 (en) 2010-10-26
EP1531153A1 (en) 2005-05-18
US20060287371A1 (en) 2006-12-21
AR013358A1 (es) 2000-12-27
IL133613A (en) 2005-11-20
CN100384834C (zh) 2008-04-30
CN1270589A (zh) 2000-10-18
EE200000013A (et) 2000-08-15
USRE41911E1 (en) 2010-11-02
USRE41895E1 (en) 2010-10-26
US8921542B2 (en) 2014-12-30
WO1999002514A3 (en) 2001-05-10
ES2322807T3 (es) 2009-06-29
NZ501198A (en) 2001-09-28
JP4090514B2 (ja) 2008-05-28
EP1493738A1 (en) 2005-01-05
EE04566B1 (et) 2005-12-15
DE69832294D1 (de) 2005-12-15
GEP20032897B (en) 2003-02-25
US8536327B2 (en) 2013-09-17
EP1019389A4 (en) 2001-11-07
HK1031731A1 (zh) 2001-06-22
DE69840693D1 (de) 2009-05-07
DE69832294T2 (de) 2006-05-24
LV12569B (en) 2001-04-20
US20130331564A1 (en) 2013-12-12
ATE309236T1 (de) 2005-11-15
US20030220295A1 (en) 2003-11-27
US7125899B2 (en) 2006-10-24
TW562802B (en) 2003-11-21
USRE43003E1 (en) 2011-12-06
HUP0103111A3 (en) 2003-01-28
BRPI9810555A8 (pt) 2017-09-19
CZ200058A3 (cs) 2001-01-17
BG104068A (en) 2000-09-29
IL133613A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
TR200000065T2 (tr) Epotilon türevleri.
DE69821985D1 (de) Ortho-anthranilamide derivate als antikoagulantien
YU25497A (sh) Postupak za dobijanje sildenafila
ATE324897T1 (de) Verwendung von noribogain derivaten zur behandlung von chemischer abhängigkeit bei säugern
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
LT2001061A (en) Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
NO20004978D0 (no) Semi-syntetiske ecteinascidiner
DE69131325D1 (de) Zwischenverbindungen zur herstellung von thioalkylthio cephalosporinderivaten
TR200002932T2 (tr) Azabisayklik 5HT1 Alıcı liganolları
DK0784055T3 (da) Pyrimidinylpyrazolderivater
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
ATE322470T1 (de) Funktionalisierte höhere diamantoide
ES2157292T3 (es) Inhibidores 6-azaindol de la tromboxano sintasa.
DE69629133D1 (de) Substituierte Aminochinazolinon (thion) Derivate
DE69707672D1 (de) Dibenzo-oxazepin- und dioxepin-derivate und ihre verwendung als antitumormittel
BR9912885A (pt) Derivado de 3-azabiciclo-[3.2.0]- heptano n-substituìdo
AU4776399A (en) Benflumetol derivatives, intermediates thereof and their use against parasiticalprotozoa and trematodes
ECSP982576A (es) Derivados de epotilona
PT1140932E (pt) Derivados de 1,8-benzonaftiridina
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.
TH26544A (th) อนุพันธ์กรด -4 - อัลคิลไทโอ -ไพรมิดิน -5 - อิล อาซีติก
EP0971889A4 (en) METHOD FOR PRODUCING INTERMEDIATE PRODUCTS OF CARBAPENEM
MX9701547A (es) Compuestos siloxi asimetricos.